Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2022-03-01 | Reverse | 1:20 |
| 2019-02-06 | Reverse | 1:10 |
| 2015-06-16 | Reverse | 2:5 |
Pulmatrix, Inc. is a biotech company developing inhaled therapies using iSPERSE technology for respiratory and other diseases, with products like Pulmazole, PUR1800, and PUR3100 in various clinical stages.

PUR3100 is a Phase 2-ready, inhaled dry powder dihydroergotamine (DHE) for acute migraine treatment, utilizing Pulmatrix's proprietary iSPERSE™ technology.
| Icon | PRODUCT | Q2-2015 | Q3-2015 | Q4-2015 |
|---|---|---|---|---|
![]() | Tiotropium Bromide Collaboration Agreement | $170K | $651K ▲ | — |
![]() | Material Transfer Agreement | — | $39K | $38K ▼ |
Overall rating: C
| PEER | PRICE | |
|---|---|---|
PALI | $2.10 | COMPARE |
LGVN | $0.84 | COMPARE |
DARE | $0.82 | COMPARE |
CTXR | $0.60 | COMPARE |
ADTX | $0.01 | COMPARE |
CRIS | $1.58 | COMPARE |
FBLG | $1.44 | COMPARE |
ASBP | $7.97 | COMPARE |